Advertisement
Screener

Cadrenal Therapeutics, Inc. (CVKD) Investing Cash Flow

2.4 / 5 stars · 11/23 Roast Me

Cadrenal Therapeutics, Inc. Investing Cash Flow

Cadrenal Therapeutics, Inc. (CVKD) reported Investing Cash Flow of $1.44 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Investing Activities

us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13

  • Cadrenal Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $0.00.
  • Cadrenal Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$1.85K.
  • Cadrenal Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-06-30 was $0.00.
  • Cadrenal Therapeutics, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-03-31 was -$3.25K.
  • Cadrenal Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$5.10K.
  • Cadrenal Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$6.54K.
  • Cadrenal Therapeutics, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$3.25K.
Period endNet Cash Provided by (Used in) Investing Activities 3 monthNet Cash Provided by (Used in) Investing Activities 6 monthNet Cash Provided by (Used in) Investing Activities 8 monthNet Cash Provided by (Used in) Investing Activities 9 monthNet Cash Provided by (Used in) Investing Activities 11 monthNet Cash Provided by (Used in) Investing Activities 12 month
2026-06-30$1.44K
10-Q · filed 2026-08-13
2025-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31
-$1.85K
derived: sum of 2 quarters · filed 2026-03-31
-$1.85K
derived: sum of 3 quarters · filed 2026-08-13
-$5.10K
10-K · filed 2026-03-31
2025-09-30-$1.85K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
-$1.85K
derived: sum of 2 quarters · filed 2026-08-13
-$5.10K
10-Q · filed 2025-11-10
2025-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$3.25K
10-Q · filed 2026-08-13
2025-03-31-$3.25K
10-Q · filed 2026-05-07
2024-12-31-$6.54K
10-K · filed 2026-03-31
2023-12-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13
-$1.00
derived: sum of 2 quarters · filed 2025-03-13
-$3.25K
10-K · filed 2025-03-13
2023-09-30-$1.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$3.25K
10-Q · filed 2024-11-07
2023-06-30-$3.25K
10-Q · filed 2024-08-07
2022-12-31-$2.28K
10-K · filed 2024-03-11
2022-09-30-$2.28K
10-Q · filed 2023-11-09

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lakewood-Amedex Biotherapeutics Inc. (LABT)United States$0.004B
REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)United States$0.005B
Dermata Therapeutics, Inc. (DRMA)United States$0.005B-0.62
60 DEGREES PHARMACEUTICALS, INC. (SXTP)United States$0.004B-0.59
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
REVELATION BIOSCIENCES, INC. (REVB)United States$0.004B
HCW Biologics Inc. (HCWB)United States$0.004B-6.15
Onconetix, Inc. (ONCO)United States$0.004B
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Aptevo Therapeutics Inc. (APVO)United States$0.003B